Eagle Pharmaceuticals Inc 's ROA from the second quarter of 2023 to the second quarter of 2022 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Eagle Pharmaceuticals Inc 's ROA in the second quarter of 2023?
Eagle Pharmaceuticals inc achieved a return on average assets (ROA) of 3.17 % in its second quarter of 2023, which is below Eagle Pharmaceuticals Inc 's average return on assets, which stands at 9.01%.

Despite the company's net income deteriorating, Eagle Pharmaceuticals Inc was able to improve its ROA compared to the first quarter of 2023.

However, within the Healthcare sector 166 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2023 quarter, so far to 1729, from total ROA ranking in the first quarter of 2023 at 3052.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2023) II. Quarter	(Mar 31 2023) I. Quarter	(Dec 31 2022) IV. Quarter	(Sep 30 2022) III. Quarter	(Jun 30 2022) II. Quarter
Y / Y Total Assets Change	4.24 %	20.72 %	49.88 %	42.4 %	36.03 %
Y / Y Net Income Change	-	-86.95 %	-	-	-
Net Income (TTM) in million	12	-3	36	21	23
Return On Assets (TTM)	3.17 %	-0.72 %	10.01 %	6.56 %	7.66 %
EGRX's Total Ranking	# 1729	# 3052	# 922	# 1218	# 1103
Total Assets (TTM) in million	375	387	380	365	359
Seq. Total Assets Change	-3.06 %	1.64 %	4.21 %	1.52 %	12.27 %
Seq. Net Income Change	-10.19 %	-29.58 %	-	-	-

EGRX's 5 Years Annual ROA >> Back to EGRX Management Effectiveness >> Compare EGRX ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 61
Sector	# 167
Overall	# 1704

Return On Assets Statistics
High	Average	Low
49.81 %	9.01 %	-24.75 %
(Mar 31 2017)		(Dec 31 2014)

Financial Statements
Eagle Pharmaceuticals Inc 's Assets	$ 375 million	EGRX's Balance sheet
Eagle Pharmaceuticals Inc 's Income	$ 5 million	Quarterly EGRX's Income Statement
EGRX's Income by Division		See EGRX's Income by Division

Annual Return On Assets	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021	(Dec 31 2020) FY 2020	(Dec 31 2019) FY 2019	(Dec 31 2018) FY 2018
Y / Y Total Assets Change	49.88 %	0.21 %	-0.54 %	6.69 %	-11.65 %
Total Assets in million	380	254	253	255	239
Y / Y Net Income Change	-	-	-16.24 %	-55.14 %	-38.58 %
Net Income in million	36	-9	12	14	32
Annual Return On Assets	9.37 %	-3.4 %	4.74 %	5.62 %	13.37 %

EGRX's 5 Years Annual ROA >> Back to EGRX Management Effectiveness >> Compare EGRX ROA to its Competitors

Comment on EGRX's ROA in the fiscal year ending 2022

In the fiscal year 2022 ROA improved to 9.37 % compared to prior year, due to annual net income growth of % to $35.64 million, while value of Eagle Pharmaceuticals Inc 's overall assets grew just by 49.88 % to $380.28 million, compared to $380.28 a year before.

More Return On Assets Ratios
EGRX's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
EGRX's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for EGRX's Competitors
Subscribers only: Roa for Eagle Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Assets for EGRX's Customers

You may also want to know
EGRX's Roi	EGRX's Inventory Turnover Ratio	EGRX's Growth Rates	EGRX's Dividend Comparisons
	EGRX's Profitability Ratios	EGRX's Asset Turnover Ratio	EGRX's Dividend Growth
EGRX's Roe	EGRX's Valuation Ratios	EGRX's Financial Strength Ratios	EGRX's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2023, within Healthcare Sector	ROA
Cv Sciences Inc	8.72 %
Gilead Sciences Inc	8.71 %
Thorne Healthtech Inc	8.38 %
Bristol myers Squibb Company	8.34 %
Progyny Inc	8.27 %
Lemaitre Vascular Inc	8.05 %
Maravai Lifesciences Holdings Inc	7.63 %
Option Care Health Inc	7.60 %
Cadre Holdings inc	7.59 %
Omeros Corporation	7.54 %
Rennova Health Inc	7.52 %
Electromed Inc	7.44 %
Neurocrine Biosciences Inc	7.44 %
Patterson Companies Inc	7.37 %
Stryker Corp	7.37 %
Encompass Health Corporation	7.31 %
Haemonetics Corporation	7.17 %
Abbott Laboratories	7.01 %
Organon and Co	6.99 %
Johnson and Johnson	6.96 %
Ensign Group Inc	6.63 %
Quest Diagnostics Inc	6.56 %
Charles River Laboratories International inc	6.44 %
Abbvie Inc	6.32 %
Dexcom Inc	6.32 %
Incyte Corporation	6.28 %
Glucotrack Inc	6.11 %
Fonar Corporation	6.10 %
Staar Surgical Co	5.96 %
Lftd Partners Inc	5.93 %

Date modified: 2026-09-26T07:17:24+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.